Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
89 EVENTS
Eisai's founder, Toyoji Naito, was born on August 15 in Ito, a village in Fukui, central Japan. He was the sixth child and third son of Kikuji Naito and his wife, Fuji.
Sakuragaoka Laboratory Co., Ltd. launched the vitamin E product Juvela through Tanabe Motosaburo Store Co., Ltd. Its chocolate‑brown coating, "hard outside, soft inside" pellets and stylish packaging attracted much attention at the time. Juvela became the laboratory's first success. Sakuragaoka Laboratory Co., Ltd. launched Sampon, Japan's first sanitary tampon, through Tanabe Motosaburo Store Co., Ltd.
World War II began.
Nihon Eisai Co., Ltd., the immediate predecessor of Eisai Co., Ltd., was established in Saitama, eastern Japan. "Origin of the Eisai Logomark"
Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merged under the name Nihon Eisai Co., Ltd.
World War II ended.
Nihon Eisai Co., Ltd.'s contraceptive suppository Sampoon, researched and developed during Japan's postwar baby boom, received official approval from the Japanese government. "Eisai Advertising Through the Years". Nihon Eisai Co., Ltd. launched the cardiotonic Neophyllin in Japan.
Nihon Eisai Co., Ltd. launched the high‑dosage vitamin B1 and B2 product Chocola BB Tablets in Japan. Nihon Eisai Co., Ltd. launched the motion sickness remedy Travelmin in Japan.
The company changed its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd., as it is known today. "Origin of the Eisai Logomark"
Eisai rolled out its first three‑year mid‑term plan. Eisai's Head Office building was completed in Tokyo.
Eisai opened its Taipei Office (now part of Eisai Taiwan Inc.), the company's first overseas branch, in Taiwan. Eisai was publicly listed in the First Section of both the Tokyo and Osaka Stock Exchanges. Gastrointestinal remedies Saclon and Saclon Tablets, recognizable for their distinct green hue even today, were launched in Japan.
Toyoji Naito received the Japan Marketing Award, which recognizes people who have made a significant contribution to marketing and advertising in Japan. The Tokyo Olympics took place.
The Kawashima Plant is completed in Gifu, central Japan. Kawashima Plant opening ceremony. Founder Toyoji Naito is appointed as chairman and Yuji Naito as company president. A three-tier representative director system is introduced: Chairman Toyoji Naito, President Yuji Naito, and Executive Vice President Tatsuo Naito.
Youda Co., Ltd. is established as a pharmaceutical imports subsidiary in Taiwan.
PT Eisai Indonesia is established as a pharmaceutical manufacturing and sales subsidiary in Indonesia. Toyoji Naito resigns as representative director and chairman to assume director and honorary chairman roles.
Toyoji opens the Naito Museum of Pharmaceutical Science and Industry, Japan's first pharmaceutical museum, in Gifu.
The first oil crisis occurs due to conflict in the Middle East.
Eisai (Malaysia) Sdn. Bhd. and Hi-Eisai Pharmaceutical Inc. are established as pharmaceutical sales subsidiaries in Malaysia and the Philippines, respectively. Metabolic cardiotonic : Neuquinon : is launched in Japan.
Naturally derived vitamin E product : Juvelux : is launched in Japan.
Eisai's founder Toyoji Naito passes away at age 89. Peripheral neuropathy treatment : Methycobal : is launched in Japan.
Eisai Asia Regional Services Pte. Ltd. is established as a sales support and management services subsidiary in Singapore.
Eisai U.S.A. Inc. is established as a chemical and pharmaceutical machinery sales subsidiary in California, the United States. The Misato Plant commences pharmaceutical manufacturing in Saitama. Large-scale automated sugar-coating equipment (pan diameter of up to 170 cm) at the Misato Plant.
The Tsukuba Research Laboratories open in Ibaraki, eastern Japan.
Eisai Chemical Co., Ltd. (now Eisai's Kashima Plant) is established in Ibaraki to manufacture active pharmaceutical ingredients (APIs).
Gastritis and gastric ulcer treatment : Selbex : is launched in Japan.
Eisai has supported of the Health and Medical Care Contributions Awards, which are presented to healthcare professionals who have contributed significantly to improving access to healthcare in difficult-to-reach areas from 1987 to 2015.
Eisai rolls out its first five-year mid-term plan.
Eisai Research Institute of Boston, Inc. (now the Boston Research Institute) is established as a discovery research subsidiary in Massachusetts, the United States.
President Yuji Naito steps down from office and assumes the role of chairman; Vice President Haruo Naito is appointed president of Eisai.
"Passing of the baton" from Yuji Naito : (right) : to Haruo Naito : (left)
Eisai America, Inc. is established as a clinical research subsidiary in New Jersey, the United States.
Eisai Europe Ltd. is established as a clinical research subsidiary in London, the United Kingdom.
Eisai Machinery GmbH is established as a pharmaceutical machinery sales subsidiary in Cologne, former West Germany.
Eisai (Thailand) Marketing Co., Ltd. is established as a pharmaceutical sales subsidiary in Bangkok, Thailand.
Haruo Naito announces Eisai's "Commitment to Innovation."
Eisai London Research Laboratories, Ltd. is established as a discovery research subsidiary attached to University College London in the United Kingdom.
Japan's bubble economy bursts.
Eisai Hong Kong Co., Ltd. is established as a pharmaceutical sales subsidiary in Hong Kong.
The Beijing Representative Office is established in Beijing, China.
Shenyang Eisai Pharmaceutical Co., Ltd. is established as a Chinese–foreign contractual joint venture in pharmaceutical manufacturing and sales in Shenyang, China.
Eisai celebrates its 50th anniversary.
Eisai adopts its current Corporate Mission and Corporate Objective.
Eisai Corporation of North America is established as a holding company in New Jersey, the United States.
Eisai London Research Laboratories, Ltd. is completed in the United Kingdom to form an Eisai Group multipolar R&D network spanning Japan, America and Europe.
Eisai London Research Laboratories opening ceremony in 1993 attended by the United Kingdom's Princess Royal, Princess Anne
Eisai Inc. is established as a pharmaceutical sales subsidiary in New Jersey, the United States.
Eisai Ltd. is established as a pharmaceutical sales subsidiary in London, the United Kingdom.
Eisai Deutschland GmbH is established as a pharmaceutical sales subsidiary in Frankfurt, Germany.
Eisai S.A. is established as a pharmaceutical sales subsidiary in Paris, France.
Eisai Suzhou Pharmaceutical Co., Ltd. is established as a pharmaceutical manufacturing and sales subsidiary in Jiangsu, China.
Elmed Eisai Co., Ltd. is established as a generic drug sales subsidiary in Tokyo.
Eisai Manufacturing Ltd. is established as a pharmaceutical manufacturing subsidiary in Hertfordshire, the United Kingdom.
Eisai acquires Morphotek Inc., a bioventure specialized in antibody research, in the United States.
Eisai Pharmatechnology & Manufacturing Pvt. Ltd. is established as an API/formulation manufacturing and R&D subsidiary in Vizag, India.
Eisai SA/NV is established as a pharmaceutical sales subsidiary in Brussels, Belgium.
Eisai acquires MGI Pharma Inc., an oncology biopharmaceutical company in the United States.
Eisai Machinery Shanghai Inc. is established as a subsidiary in Shanghai, China to provide marketing support and maintenance services for pharmaceutical machinery.
Rheumatoid arthritis treatment Humira is launched in Japan.
Eisai GesmbH is established as a pharmaceutical sales subsidiary in Vienna, Austria.
The European Knowledge Centre (now EMEA Knowledge Centre) opens as a European strategic base in Hertfordshire, the United Kingdom.
EMEA Knowledge Centre: The Eisai Product Creation Systems organizational structure is introduced Group-wide to reflect a new focus on patient-oriented R&D.
Haruo Naito is appointed as president of the International Federation of Pharmaceutical Manufacturers & Associations.
The Eisai Knowledge Centre, India opens as a manufacturing and process research base in Vizag, India.
The Koishikawa Knowledge Center opens in Tokyo and receives the 24th Nikkei New Office Promotion Award.
Koishikawa Knowledge Center: Eisai Limited is established as a pharmaceutical sales subsidiary in Ontario, Canada.
Production headquarters transforms to a global “Eisai Demand Chain Systems” structure to reflect a new “demand-driven” customer satisfaction focus in drug manufacturing.
Eisai (Suzhou) Trading Co., Ltd. is established as a pharmaceutical trading subsidiary in Jiangsu, China.
Anticancer agent Halaven is launched in the United States.
Eisai signs a statement with the World Health Organization (WHO) to supply a primary lymphatic filariasis medicine free of charge.
H3 Biomedicine Inc. is established as a research subsidiary in the United States.
The Great East Japan Earthquake strikes.
Eisai rolls out its sixth mid-term plan, “HAYABUSA.”
Eisai Participações Ltda. is established as a pharmaceutical sales subsidiary in São Paulo, Brazil.
Halaven is launched in Europe and Japan.
Eisai Laboratorios S. de R.L. de C.V. is established as a pharmaceutical sales subsidiary in Mexico City, Mexico.
Eisai signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020.
Haruo Naito is appointed as president of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ).
Antiepileptic agent Fycompa is launched in Europe.
Eisai Israel Ltd. is established as a pharmaceutical sales subsidiary in Tel Aviv, Israel.
Eisai and Biogen amend collaboration agreements on : ADUHELM : .
Eisai makes Arteryex Inc., a company that plans and develops software, its subsidiary.
Eisai Pharmaceuticals Africa (Pty) Ltd is established as a pharmaceutical sales subsidiary in Johannesburg, South Africa.
Eisai signs the public private partnership “Kigali Declaration” for eliminating neglected tropical diseases.
Deep Human Biology Learning (DHBL), a new R&D organization, commences full-scale operation.
Alzheimer’s disease treatment : LEQEMBI : is granted accelerated approval and launched in the United States.
Eisai commits funding to the 3rd phase of Global Health Innovative Technology Fund.
LEQEMBI : is granted traditional approval by the FDA.
Theoria technologies Co., Ltd. is established as a digital business company in Tokyo, Japan.
LEQEMBI : is launched in Japan.
§07
News
109 ARTICLES
Environmental Action Across the Eisai Group
Guided by its human health care (hhc) concept, Eisai Group aims to improve health and well-being and contribute to social good. Recognizing that people’s health depends on a healthy global environment, the group works to reduce the environmental impact of its business and encourage employees to deepen their understanding of environmental issues and act on it.
Learning Global Health Through Everyday Topics
Eisai supports global health through initiatives such as improving access to medicines in developing countries and developing treatments for neglected tropical diseases. During summer vacation, Sustainability Department members visited after-school childcare facilities to help children learn about global health.
A Closer Look at São Tomé and Príncipe
The feature introduces São Tomé and Príncipe through the impressions of Miwa Jindo of Eisai’s Sustainability Department, who attended a May 29, 2026 meeting there. The meeting launched the final surveillance activities under the WHO program to eliminate lymphatic filariasis.
Eisai Retained in All Six GPIF ESG Indices
For 2026, Eisai remains a constituent of all six Japanese equity ESG indices adopted by Japan’s Government Pension Investment Fund (GPIF). The company was also selected for the FTSE4Good Index Series and MSCI Selection Indexes.
Eisai’s Mycetoma Efforts in SDGs Talk
Eisai’s efforts to develop treatments for mycetoma were featured in “SDGs Talk,” a global health discussion series published by the GHIT Fund. The fund supports the development of drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases through public-private partnerships.
Final Surveillance for Filariasis Elimination
São Tomé and Príncipe has begun final surveillance toward eliminating lymphatic filariasis as a public health problem. Eisai has supported the initiative since 2018, including by providing diethylcarbamazine (DEC) tablets free of charge, and attended a launch meeting on May 29, 2026.
Eisai Selected for SOMPO Sustainability Index
Eisai Co., Ltd. was selected for the SOMPO Sustainability Index for FY2026, continuing its listing since the index began in FY2012. The index comprises approximately 300 companies recognized for ESG initiatives, with constituents reviewed annually based on environmental and ESG management surveys.
Eisai Wins Top Score in CDP Supplier Engagement Assessment
Eisai received the highest rating of "Supplier Engagement Leader" in the CDP Supplier Engagement Assessment. This is the second consecutive award, following last year, and in 2025 it was selected for the A-list in the areas of "Climate Change" and "Water Security".
Kawashima Plant Wins Gifu Decarbonization Award
Eisai’s Kawashima Plant in Kakamigahara, Gifu Prefecture, was selected for the newly established Gifu Decarbonization Top Runner Award in recognition of its proactive greenhouse gas reduction efforts. Launched by Gifu Prefecture in fiscal 2025, the award aims to accelerate reductions in greenhouse gas emissions from business activities in the prefecture.
Eisai Wins Human Capital Awards for Third Year
Eisai was selected for “Thought Leaders of Human Capital 2025” and the “Human Capital Management Excellence 2025 Gold Award,” marking its third consecutive year of recognition. The awards were based on the Human Capital Survey 2025, which involved 316 companies and organizations.